eye immunology
TRANSCRIPT
![Page 1: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/1.jpg)
Ophthalmic immunology
![Page 2: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/2.jpg)
Protective mechanisms
![Page 3: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/3.jpg)
Question.1
![Page 4: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/4.jpg)
Diversity Vs Tolerance
Question.2
![Page 5: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/5.jpg)
Tolerance
Clonal DeletionReceptor editingAnergyIgnoranceDownregulation by: Treg
![Page 6: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/6.jpg)
Diversity Vs Tolerance
![Page 7: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/7.jpg)
Mechanisms of immune privilege in the eye
First, the eye is filled with immunosuppressive factors including:
• neuropeptides• melanocyte stimulating hormone• somatostatin • vasoactive intestinal peptide • calcitonin gene related peptide • cytokines (e.g. TGFβ-2)• complement inhibitors • inhibitor of NK cell activity (macrophage inhibitory factor) .
![Page 8: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/8.jpg)
Mechanisms of immune privilege in the eye
• Second, the low expression of MHC class II in the eye limits antigen presentation.
![Page 9: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/9.jpg)
Mechanisms of immune privilege in the eye
• Third, stromal cells from the iris, ciliary body and retina of the eye are able to convert immune T cells to regulatory (Treg) cells .
Furthermore retinal pigment epithelial (RPE) cells that line the borders of the eye are able to directly inhibit primed T cells.
![Page 10: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/10.jpg)
Mechanisms of immune privilege in the eye
• Fourth, death inducing molecules like PDL-1 and FasL are expressed by stromal cells in the eye and induce apoptosis of immune cells that transgress ocular boundaries
![Page 11: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/11.jpg)
Mechanisms of immune privilege in the eye
• Fifth, Immobility of Dendritic Cells Within the Anterior Chamber and Anterior Chamber Associated Immune Deviation
failure of these antigen-bearing cells to migrate to the local lymph nodes . The inability to migrate is consistent with the known lack of lymphatics within the eye
Immune response without inflammationImmune response without inflammation
![Page 12: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/12.jpg)
Anterior chamber associated immune deviation
In this model, the placement of antigen into the anterior chamber of the eye induces a characteristic immune response that includes the absence of complement fixing antibodies and Th1 and Th2 immune responses specifically to that antigen. However, the animal remains perfectly capable of responding to the antigen.
![Page 13: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/13.jpg)
Generation of Foxp3+ CD8+ Treg cells :T-cell receptor α-chain fragments from apoptotic cells arepresented in the class I pathway. This event generates CD8 killer cells,which are capable of deleting the CD4 T cells
![Page 14: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/14.jpg)
![Page 15: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/15.jpg)
a. Cross-Immunization
b. Co-Stimulation of anergic clones
by superantigen
Termination of Tolerance
![Page 16: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/16.jpg)
Immunological Pathomechanisms
![Page 17: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/17.jpg)
HLA-B27 ≈ arrestinHLA-B27 ≈ arrestin
![Page 18: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/18.jpg)
Conjunctivitis
![Page 19: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/19.jpg)
Keratitis
![Page 20: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/20.jpg)
Scleritits and Uveitis
![Page 21: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/21.jpg)
Termination of Tolerance
![Page 22: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/22.jpg)
Scleritits
![Page 23: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/23.jpg)
Uveitis
![Page 24: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/24.jpg)
Uveitis
![Page 25: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/25.jpg)
Uveitis
![Page 26: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/26.jpg)
Uveitis
![Page 27: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/27.jpg)
Panuveitis
Presentation of auto antigen because of MHC II expression on melanocyte perhaps to viral infection
![Page 28: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/28.jpg)
Uveitic condition in sympathic ophthalmia
![Page 29: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/29.jpg)
![Page 30: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/30.jpg)
Inflammation of the pars plana, a part of the ciliary body.
![Page 31: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/31.jpg)
Therapeutic implicationsTherapeutic implications• T cell–targeting therapies such as: cyclosporine, FK-506, and rapamycin, which are already FDA
approved and in clinical use and Humanized CD25-specific antibody (daclizumab)
• Anti-TNF therapy
• IFN-α is being used with considerable success to treat uveitis in patients with Behçet disease and has been approved in Europe
• Oral tolerance to arrestin
• IL-17 neutralization therapy
• Blockade of the chemokine receptors CXCR3 and CXCR5
• VLA4-specific monoclonal antibody is an FDA approved treatment for multiple sclerosis and Crohn disease
![Page 32: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/32.jpg)
![Page 33: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/33.jpg)
• Why are mismatched cadaver cornea grafts accepted 60–70% of the time in humans?
Post-transplant event: These events are local episodes of alloantigen independent inflammation, such as a loosened transplant suture, bacterial suture-associated infection, or herpetic infection recurrence. These lead to recruitment of alloreactive cells, angiogenesis, lymphangiogenesis, and upregulation of MHC molecules on the graft cells, and sequelae, which in combination lead to an acute onset rejection response.
When antigen injected into the anterior chamber , vitreous or sub-retinal space induces peripheral tolerance to that antigen.
![Page 34: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/34.jpg)
Phcogenic Uveitis
![Page 35: EYE IMMUNOLOGY](https://reader035.vdocuments.mx/reader035/viewer/2022081502/55304d4a4a7959b8338b4669/html5/thumbnails/35.jpg)
AIDS
• Because cotton-wool spots are an early sign of AIDS, the ophthalmologist may be the first physician to alert the patient to the existence of this serious disorder.